Teva sees obstacles to copying GSK's Advair drug before 2018

LONDON (Reuters) - Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling lung drug Advair that could be sold as a true substitute to U.S. patients before 2018.

Source: Reuters: Health - October 8, 2013 Category: Consumer Health News Tags: healthNews Source Type: news